AU2001272738A1 - Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma - Google Patents

Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Info

Publication number
AU2001272738A1
AU2001272738A1 AU2001272738A AU7273801A AU2001272738A1 AU 2001272738 A1 AU2001272738 A1 AU 2001272738A1 AU 2001272738 A AU2001272738 A AU 2001272738A AU 7273801 A AU7273801 A AU 7273801A AU 2001272738 A1 AU2001272738 A1 AU 2001272738A1
Authority
AU
Australia
Prior art keywords
glaucoma
treating
composition containing
ocular hypertension
prostaglandin compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272738A
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2001272738A1 publication Critical patent/AU2001272738A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
AU2001272738A 2000-07-20 2001-07-18 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma Abandoned AU2001272738A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62041600A 2000-07-20 2000-07-20
US09/620,416 2000-07-20
US09/734,692 US20020035148A1 (en) 2000-07-20 2000-12-13 Treatment of ocular hypertension
US09/734,692 2000-12-13
PCT/JP2001/006211 WO2002007731A2 (en) 2000-07-20 2001-07-18 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
AU2001272738A1 true AU2001272738A1 (en) 2002-02-05

Family

ID=27088716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272738A Abandoned AU2001272738A1 (en) 2000-07-20 2001-07-18 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Country Status (7)

Country Link
US (3) US20020035148A1 (en)
EP (1) EP1317269A2 (en)
JP (1) JP2004504350A (en)
KR (1) KR20030016418A (en)
AU (1) AU2001272738A1 (en)
CA (1) CA2416681A1 (en)
WO (1) WO2002007731A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20040254247A1 (en) * 2001-07-31 2004-12-16 Ryuji Ueno Method and composition for treatnment of ocular hypertension and glaucoma
EP1411950A2 (en) * 2001-07-31 2004-04-28 Sucampo AG Treatment of ocular hypertension and glaucoma
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20030060511A1 (en) * 2001-08-23 2003-03-27 Sucampo Ag Method for treatment of ocular hypertension and glaucoma
JP2005526092A (en) * 2002-03-21 2005-09-02 ケイマン ケミカル カムパニー Prostaglandin F2α analogues and their combined use with antibacterial proteins for the treatment of glaucoma and increased intraocular pressure
JP2005519978A (en) * 2002-03-28 2005-07-07 スキャンポ・アーゲー Methods for treating ocular hypertension and glaucoma
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP1953541B1 (en) * 2005-11-16 2014-05-07 Mitsubishi Gas Chemical Company, Inc. Method for determination of amount of double-stranded dna
EP2317971B1 (en) * 2008-03-19 2015-07-29 Ciro Caruso Composition for stimulating the growth of eyelashes, eyebrows and hairs
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
TWI680975B (en) 2018-06-26 2020-01-01 奇鈦科技股份有限公司 Uv absorbing compound and applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455264B1 (en) * 1987-09-18 1994-07-13 R-Tech Ueno Ltd. Ocular hypotensive agents
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE1300150T1 (en) 1988-09-06 2003-09-18 Pharmacia Ab Prostaglandin derivatives used to treat glaucoma or hypertension
ATE111736T1 (en) * 1988-10-01 1994-10-15 R Tech Ueno Ltd OCULAR HYPOTENSIVE REMEDIES.
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ES2203103T3 (en) * 1998-04-07 2004-04-01 Alcon Manufacturing Ltd. GELIFYING OPHTHALMIC COMPOSITIONS CONTAINING XANTANA GUM.
HUP0300391A3 (en) * 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma

Also Published As

Publication number Publication date
US6596765B2 (en) 2003-07-22
CA2416681A1 (en) 2002-01-31
WO2002007731A2 (en) 2002-01-31
US20020035148A1 (en) 2002-03-21
KR20030016418A (en) 2003-02-26
EP1317269A2 (en) 2003-06-11
JP2004504350A (en) 2004-02-12
WO2002007731A3 (en) 2003-04-03
US20030220395A1 (en) 2003-11-27
US20020035149A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001272738A1 (en) Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
PT1392319E (en) Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same
EP1514548A3 (en) Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension
AU4292096A (en) Use of guanylate cyclase inhibitors for reducing intraocular pressure
CA2315829A1 (en) Angiostatic agents and compositions for controlling ocular hypertension
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
AU7256296A (en) Use of metallofluorocomplexes for dental compositions
AU4327300A (en) Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
AU2001233081A1 (en) Composition for treatment of stress
AU2003223224A1 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
HK1061645A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
IL133871A0 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU7810198A (en) Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
AU3328601A (en) Internal 1,15-lactones of fluprostenol and related prostaglandin F<sub>2alpha</sub> analogs and their use in the treatment of glaucoma and intraocular hypertension
AU2603301A (en) 6-keto prostaglandin F1alpha and analogs for treating dry eye
AU2002218337A1 (en) Method for inducing cognition enhancement by use of trimethyl-bicyclo(2.2.1)heptane derivatives
HK1024170A1 (en) Remedial composition for intraocular hypertension or glaucoma
WO2002072105A3 (en) Improved prostanoid therapies for the treatment of glaucoma
AU2155995A (en) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
HUP0300391A3 (en) Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma
CA2214386A1 (en) Optically active thiazolidinone derivatives
CA2356912A1 (en) Pharmaceutical compositions for the treatment of ocular hypertension or glaucoma
WO1996021670A3 (en) Antifungal fusacandins
AU2001270642A1 (en) Method for the treatment of glaucoma and ocular hypertension by administering nucleotides